TEG® and RapidTEG® are unreliable for detecting warfarin-coagulopathy: a prospective cohort study

Thrombosis Journal

David A Hoffman³  Alddo A Molinar¹  Mark T Shima²  Elisha A Chance²  Jason Schiraldi⁴  Barbara M Hileman²  Charlene Rabel⁵  C Michael Dunham² 

[1] Department of Anesthesiology, St. Elizabeth Health Center, 1044 Belmont Avenue, Youngstown, OH 44501, USA;Trauma/Critical Services, St. Elizabeth Health Center, 1044 Belmont Avenue, Youngstown, OH 44501, USA;Division of Cardiology, St. Elizabeth Health Center, 1044 Belmont Avenue, Youngstown, OH 44501, USA;Electrophysiology Service, St. Elizabeth Health Center, 1044 Belmont Avenue, Youngstown, OH 44501, USA;Central Laboratory Services, St. Elizabeth Health Center, 1044 Belmont Avenue, Youngstown, OH 44501, USA

关键词: Coagulopathy;    Thromboelastography;    Warfarin;   

Others  :  834727
DOI  :  10.1186/1477-9560-12-4

 received in 2013-11-03, accepted in 2014-01-28,  发布年份 2014

【 摘 要 】

Background

Thromboelastography® (TEG) utilizes kaolin, an intrinsic pathway activator, to assess clotting function. Recent published studies suggest that TEG results are commonly normal in patients receiving warfarin, despite an increased International Normalized Ratio (INR). Because RapidTEG™ includes tissue factor, an extrinsic pathway activator, as well as kaolin, we hypothesized that RapidTEG would be more sensitive in detecting a warfarin-effect.

Methods

Included in this prospective study were 22 consecutive patients undergoing elective cardioversion and receiving warfarin. Prior to cardioversion, blood was collected to assess INR, Prothrombin Time, TEG, and RapidTEG.

Results

INR Results: 2.8 ± 0.5 (1.6 to 4.2). Prothrombin Time Results: 19.1 ± 2.2 (13.9. to 24.3).

TEG Results (Reference Range): R-Time: 8.3 ± 2.7 (2–8); K-Time: 2.1 ± 1.4 (1–3); Angle: 62.5 ± 10.3 (55–78); MA: 63.2 ± 10.3 (51–69); G: 9.4 ± 3.5 (4.6-10.9); R-Time within normal range: 10 (45.5%) with INR 2.9 ± 0.3; Correlation coefficients for INR and each of the 5 TEG variables were insignificant (P > 0.05).

RapidTEG Results (Reference Range): ACT: 132 ± 58 (86–118); K-Time: 1.2 ± 0.5 (1–2); Angle: 75.4 ± 5.2 (64–80); MA: 63.4 ± 5.1 (52–71); G: 8.9 ± 2.0 (5.0-11.6); ACT within normal range: 9 (40.9%) with INR 2.7 ± 0.5; Correlation coefficients for INR and each of the 5 RapidTEG variables were insignificant (P > 0.05).

Conclusions

TEG, using kaolin activation, and RapidTEG, with kaolin and tissue factor activation, were normal in a substantial percent of warfarin patients, despite an increased INR. The false-negative rate for detecting warfarin coagulopathy with either test is unacceptable. The lack of correlation between INR and all TEG and RapidTEG components further indicates that these methodologies are insensitive to warfarin effects. Findings suggest that intrinsic pathway activation may mitigate detection of an extrinsic pathway coagulopathy.

【 授权许可】

   
2014 Dunham et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Wysowski DK, Nourjah P, Swartz L: Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007, 167(13):1414-1419.
• [2]Dossett LA, Riesel JN, Griffin MR, Cotton BA: Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch surg (Chic, Ill : 1960) 2011, 146(5):565-570.
• [3]Ganter MT, Hofer CK: Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg 2008, 106(5):1366-1375.
• [4]Lang T, von Depka M: Possibilities and limitations of thrombelastometry/thromboelastography. Hamostaseologie 2006, 26(Suppl 1):S21-S29.
• [5]Bolliger D, Seeberger MD, Tanaka KA: Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012, 26(1):1-13.
• [6]MacDonald SG, Luddington RJ: Critical factors contributing to the thromboelastography trace. Semin Thromb Hemost 2010, 36(7):712-722.
• [7]Chen A, Teruya J: Global hemostasis testing thromboelastography: old technology, new applications. Clin Lab Med 2009, 29(2):391-407.
• [8]Rumph B, Bolliger D, Narang N, Molinaro RJ, Levy JH, Szlam F, Tanaka KA: In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. J Cardiothorac Vasc Anesth 2010, 24(3):408-412.
• [9]Nascimento B, Al Mahoos M, Callum J, Capone A, Pacher J, Tien H, Rizoli S: Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. Transfusion 2012, 52(1):7-13.
• [10]Hepner DL, Concepcion M, Bhavani-Shankar K: Coagulation status using thromboelastography in patients receiving warfarin prophylaxis and epidural analgesia. J Clin Anesth 2002, 14(6):405-410.
• [11]Reikvam H, Steien E, Hauge B, Liseth K, Hagen KG, Storkson R, Hervig T: Thrombelastography. Transfus Apher Sci 2009, 40(2):119-123.